Ratings MorphoSys AG Deutsche Boerse AG

Equities

MOR2

US6177602025

Market Closed - Deutsche Boerse AG Other stock markets 03:03:09 2024-06-14 EDT			5-day change	1st Jan Change
16.7 ^EUR	+0.60%		+1.83%	+98.81%

06-10	MorphoSys AG(XTRA:MOR) dropped from S&P Global BMI Index	CI
06-06	MorphoSys AG Announces Board Changes	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MORPHOSYS AG	+98.81%	2.66B	-
MODERNA, INC.	+40.80%	53.67B	B-
LONZA GROUP AG	+35.79%	38.86B	A
IQVIA HOLDINGS INC.	-8.05%	38.76B	B
CELLTRION, INC.	-8.98%	27.27B	C
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B	B-
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B	B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B	B+
MEDPACE HOLDINGS, INC.	+28.51%	12.18B	C+
BIO-TECHNE CORPORATION	-1.67%	11.96B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes